CAR-T cell therapies have reshaped oncology. For patients with refractory hematological malignancies who have exhausted other treatment options, a CAR-T infusion can bring the disease into complete remission. What sets these therapies apart from virtually all other pharmaceutical products doesn't begin in the operating room — it begins in the cryo lab.
Every CAR-T batch is patient-specific or lot-critical. A lost sample, a temperature excursion during transport, a mix-up in the laboratory — these errors are not correctable. That makes CAR-T cryogenic infrastructure a medical safety system.
In autologous therapies (e.g., tisagenlecleucel / Kymriah®, axicabtagene ciloleucel / Yescarta®), the patient's own T cells are collected, genetically modified outside the body, and re-infused. Cryostorage occurs at two stages:
Apheresis material: Short-term storage of leukapheresis raw material before the GMP manufacturing process
Final product: Cryogenic storage of the patient-specific, released CAR-T product until infusion
Each of these phases requires unbroken traceability and strict segregation from other batches.
Allogeneic approaches use donor T cells processed into CAR-T products and stored in batches for multiple patients. Here, batch integrity and cross-contamination risk are the central concerns.
The therapeutic efficacy of CAR-T products depends directly on cell condition after thawing. Suboptimal freezing doesn't just reduce viability — it can alter CAR expression on the cell surface and affect the expansion capacity of cells post-transduction.
The BIOFREEZE® SMARTLINE from Consarctic® is the clinically proven freezing device for CAR-T applications:
For autologous products, physical and documentary segregation of batches from different patients is the most critical requirement. This means:
The Consarctic® BSD+ tank in vapor-phase configuration is designed for this requirement: no cross-contamination risk, a clear cassette positioning system, and full monitoring connectivity.
CAR-T products must be transported after manufacturing from the GMP site to the infusion clinic — often over long distances, within tight time windows, and with absolute temperature security.
The Consarctic® ASR+ dry shipper series is developed for this transport:
Vapor-phase cryogenic tanks (Consarctic® BSD+ or BSF+) combined with the BIOFREEZE® SMARTLINE as freezing device and the Consarctic® Monitoring-System. This combination meets GMP Annex 13 requirements for ATMP cryostorage: validated freezing, vapor-phase storage without cross-contamination risk, and a continuous audit trail.
Technically possible, but regulatorily and practically problematic for patient-specific autologous products in multi-patient tanks due to cross-contamination risk. Vapor phase is the preferred and regulatorily safer option for CAR-T.
Most validated CAR-T products have an approved shelf life of 12–24 months at –196°C. Longer storage requires dedicated stability data for the specific product formulation.
Yes. Different media formulations, cryobag volumes, and cell concentrations can affect the optimal freeze protocol. The BIOFREEZE® SMARTLINE enables product-specific protocols and their complete validation for regulatory submission.
CAR-T therapies are living medicines — and their cryogenic infrastructure is an integral part of the therapy chain, not background infrastructure. Anyone planning or operating a CAR-T unit needs cryogenic systems designed for these requirements.
Consarctic GmbH is the system partner that delivers BIOFREEZE®, BSD+/BSF+ tanks, ASR+ transport, and monitoring system as an integrated solution — with complete GMP qualification.